1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Lilly Looks For Japan Rebound After Hit From LOEs

 
• By Lisa Takagi

Although Lilly Japan's 2022 sales declined 13% on the losses of exclusivity for two important products, the subsidiary has high hopes for three new drugs and other indication expansions. Its first-ever decentralized clinical trial involving Japanese patients, for Alzheimer's candidate donanemab, also turned out successfully.

Lilly sees the Japanese market as the largest market for the firm outside the US
Lilly sees the Japanese market as the largest market for the firm outside the US • Source: Shutterstock

Eli Lilly and Company's Japanese subsidiary saw its sales fall by 13% to JPY216.7bn ($1.57bn) in calendar 2022, hit by the impact of two major local patent expirations and generic competition for its antidepressant Cymbalta (duloxetine) and Alimta (pemetrexed) for non-small cell lung cancer.

Country president Simone Thomsen told a media conference in Tokyo the impact was “not unexpected” and pointed to two new product launches plus four expansions of indications bringing hope for a performance recovery this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia